ImmunityBio's Legal and Expansion Timelines Converge Under Scrutiny

ImmunityBio reports $44.2M in Q1 revenue but faces a securities lawsuit over FDA warning and a critical deadline for its Dunkirk facility, while advancing its bladder cancer trial.

ImmunityBio finds itself navigating a critical period defined by a stark contrast between robust commercial performance and escalating external pressures. The biotech firm's first-quarter 2026 preliminary net product revenue surged to $44.2 million, a staggering 168% increase year-over-year, driven by its commercial cancer drug ANKTIVA. This financial strength arrives just as the company faces a tightening web of legal and regulatory deadlines.

A second major US law firm, Kessler Topaz Meltzer & Check, has now filed a securities class action against the company. The lawsuit stems from a late March 2026 report detailing a warning letter from the U.S. Food and Drug Administration (FDA). The agency reprimanded CEO Patrick Soon-Shiong for claims made in a podcast that ANKTIVA could "cure and even prevent all cancers." Following this news, the stock plummeted more than 21% in a single day. In response, ImmunityBio has submitted a comprehensive statement to the FDA, removed the podcast from its website, halted planned television advertising, and pledged stricter internal controls. Investors have until May 26, 2026, to join as lead plaintiffs in the case filed in a California federal court.

Simultaneously, a long-dormant manufacturing facility in Dunkirk, New York, presents both a new obligation and a potential future asset. Having acquired the site following the bankruptcy of previous owner Athenex, ImmunityBio has signed a new state lease with drastically altered terms. The annual rent has jumped from a nominal one dollar to $525,000. The agreement comes with strict milestones: production with at least 100 employees must commence by the end of December 2028. If achieved, the company can purchase the facility for one dollar in early 2029, with employment targets rising to 450 people by 2032. State officials have indicated they will seek other manufacturers if these goals are missed. A key decision on a new tax agreement for the Dunkirk site, which involves a review of state compliance, is due on April 28, 2026.

The company's clinical development pipeline continues to advance independently of these challenges. The pivotal QUILT-2.005 Phase 3 study for bladder cancer is now fully enrolled, paving the way for a supplemental Biologics License Application (sBLA) submission later this year. Financially, ImmunityBio reported a solid cash position of approximately $381 million as of the end of March, providing a buffer as it manages these concurrent legal, regulatory, and operational timelines.